Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ADIL vs XMAX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ADIL Wins Head-to-Head Institutional Verdict (3–0 across 6 Pillars · 7–1 Matrix Metrics)

ADIL Overall Winner 6-Pillar Tally: ADIL 3 – 0 XMAX (3 Tie) Matrix Metrics: ADIL 7 – 1 XMAX

As of Nov 20, 2026, Adial Pharmaceuticals, Inc (ADIL) is the stronger overall head-to-head candidate over XMAX (XMAX) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ADIL carries a Unified Composite Score of 32.8/100 (SELL) at $5.05 (N/M Forward P/E, 0.0% operating margin), whereas XMAX carries 46.4/100 (HOLD) at $6.01 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While XMAX currently prints a higher short-term Unified Composite Score (46.4/100 HOLD vs. ADIL 32.8/100 SELL), ADIL captures the overall institutional head-to-head verdict (7–1 matrix metrics and 3–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: ADIL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.9); meanwhile XMAX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ADIL vs XMAX
ADIL NASDAQ Head-to-Head Winner
Adial Pharmaceuticals, Inc
Pharmaceutical Preparations
$5.05
+36.12% 1D
Market Cap $9.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.63β · 153% Vol
Unified Composite Score
32.8 / 100 SELL
Tech 5.0 Fund 36.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.6% over 20 days), RSI 63
RSI-14: 62.9 · SMA20: $3.85 · SMA50: $4.75
XMAX US Equity
XMAX
Institutional Equity
$6.01
+0.33% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.90β · 195% Vol
Unified Composite Score
46.4 / 100 HOLD
Tech 45.0 Fund 49.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.7%), weak momentum, RSI 43
RSI-14: 43.4 · SMA20: $6.26 · SMA50: $7.69

6-Pillar Scorecard Institutional Category Breakdown (ADIL 3 – 0 XMAX)

Columns: Metric · ADIL · XMAX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ADIL
Revenue Growth (YoY) +0.0% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) N/A N/A
Market Cap $9.7M N/A
3. Profitability & Quality ADIL
Gross Margin N/A N/A
Operating Margin 0.0% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -2011.6% N/A
4. Balance Sheet & Cash Flow ADIL
Cash Generation (TTM) -$6.5M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage -2011.6% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ADIL (7) vs XMAX (1)
Institutional Metric ADIL XMAX Criterion Row Edge
Market Capitalization
Scale
$9.7M N/A Larger Scale ADIL
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% N/A Higher Growth ADIL
Operating Margin (TTM)
Profitability
0.0% N/A Higher Margin ADIL
Net Profit Margin
Profitability
0.0% N/A Higher Margin ADIL
Return on Equity (ROE)
Capital Efficiency
-2011.6% N/A Higher ROE ADIL
52-Week Range Position
Momentum
70% ($0–$7) 47% ($3–$9) Stronger Trend ADIL
Beta / 30D Volatility
Risk Regime
0.63β · 153% Vol 1.90β · 195% Vol Lower Realized Risk ADIL
Unified Institutional Score
Composite Signal
32.8 / 100 (SELL) 46.4 / 100 (HOLD) Higher Composite XMAX
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$6.5M (-2011.6% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ADIL +27.24 pp
ADIL: +21.69% · XMAX: -5.55%
3M Horizon ADIL +60.34 pp
ADIL: +53.5% · XMAX: -6.84%
6M Horizon ADIL +210.24 pp
ADIL: +213.66% · XMAX: +3.42%
1Y Horizon ADIL +210.24 pp
ADIL: +213.66% · XMAX: +3.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ADIL vs XMAX. Trailing 12-month operating profitability (ADIL 0.0% vs XMAX N/A) and valuation multiples (ADIL N/M vs XMAX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ADIL ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-2011.6% · N/M
XMAX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ADIL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ADIL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XMAX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XMAX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ADIL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
XMAX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ADIL vs XMAX Key Questions & Quantitative Answers

As of Nov 20, 2026, Adial Pharmaceuticals, Inc (ADIL) is the stronger overall head-to-head candidate over XMAX (XMAX) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ADIL carries a Unified Composite Score of 32.8/100 (SELL) at $5.05 (N/M Forward P/E, 0.0% operating margin), whereas XMAX carries 46.4/100 (HOLD) at $6.01 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While XMAX currently prints a higher short-term Unified Composite Score (46.4/100 HOLD vs. ADIL 32.8/100 SELL), ADIL captures the overall institutional head-to-head verdict (7–1 matrix metrics and 3–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: ADIL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.9); meanwhile XMAX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ADIL leads the Growth & Scale pillar: ADIL posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with XMAX at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ADIL generates N/A in USD-normalized revenue versus N/A for XMAX. In operating R&D and SG&A reinvestment, ADIL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XMAX.

ADIL and XMAX trade at balanced relative valuation multiples. ADIL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas XMAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADIL (-2011.6% ROE) versus XMAX (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ADIL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.63β · 153% Vol realized risk). By comparison, XMAX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.90β · 195% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.